The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
GSK is upping its spend in neurodegenerative diseases after signing a drug discovery deal with South Korea’s ABL Bio.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.
In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.
The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.
